Literature DB >> 19283923

Perioperative tyrosine kinase inhibitors for GIST: standard ... or an idea that needs further investigation?

Margaret von Mehren1, James C Watson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19283923      PMCID： PMC2861343     

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN： 0890-9091            Impact factor:   2.990


× No keyword cloud information.
  9 in total

1.  Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.

Authors:  George D Demetri; Allan T van Oosterom; Christopher R Garrett; Martin E Blackstein; Manisha H Shah; Jaap Verweij; Grant McArthur; Ian R Judson; Michael C Heinrich; Jeffrey A Morgan; Jayesh Desai; Christopher D Fletcher; Suzanne George; Carlo L Bello; Xin Huang; Charles M Baum; Paolo G Casali
Journal:  Lancet       Date:  2006-10-14       Impact factor: 79.321

2.  KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours.

Authors:  Maria Debiec-Rychter; Raf Sciot; Axel Le Cesne; Marcus Schlemmer; Peter Hohenberger; Allan T van Oosterom; Jean-Yves Blay; Serge Leyvraz; Michel Stul; Paolo G Casali; John Zalcberg; Jaap Verweij; Martine Van Glabbeke; Anne Hagemeijer; Ian Judson
Journal:  Eur J Cancer       Date:  2006-04-18       Impact factor: 9.162

3.  Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST.

Authors:  Alessandro Gronchi; Marco Fiore; Francesca Miselli; Maria Stefania Lagonigro; Paola Coco; Antonella Messina; Silvana Pilotti; Paolo Giovanni Casali
Journal:  Ann Surg       Date:  2007-03       Impact factor: 12.969

4.  Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors.

Authors:  Chandrajit P Raut; Matthew Posner; Jayesh Desai; Jeffrey A Morgan; Suzanne George; David Zahrieh; Christopher D M Fletcher; George D Demetri; Monica M Bertagnolli
Journal:  J Clin Oncol       Date:  2006-05-20       Impact factor: 44.544

5.  Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.

Authors:  Haesun Choi; Chuslip Charnsangavej; Silvana C Faria; Homer A Macapinlac; Michael A Burgess; Shreyaskumar R Patel; Lei L Chen; Donald A Podoloff; Robert S Benjamin
Journal:  J Clin Oncol       Date:  2007-05-01       Impact factor: 44.544

6.  Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial.

Authors:  Jaap Verweij; Paolo G Casali; John Zalcberg; Axel LeCesne; Peter Reichardt; Jean-Yves Blay; Rolf Issels; Allan van Oosterom; Pancras C W Hogendoorn; Martine Van Glabbeke; Rossella Bertulli; Ian Judson
Journal:  Lancet       Date:  2004 Sep 25-Oct 1       Impact factor: 79.321

7.  Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

Authors:  Charles D Blanke; Cathryn Rankin; George D Demetri; Christopher W Ryan; Margaret von Mehren; Robert S Benjamin; A Kevin Raymond; Vivien H C Bramwell; Laurence H Baker; Robert G Maki; Michael Tanaka; J Randolph Hecht; Michael C Heinrich; Christopher D M Fletcher; John J Crowley; Ernest C Borden
Journal:  J Clin Oncol       Date:  2008-02-01       Impact factor: 44.544

8.  Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate.

Authors:  Piotr Rutkowski; Zbigniew Nowecki; Pawel Nyckowski; Wirginiusz Dziewirski; Urszula Grzesiakowska; Anna Nasierowska-Guttmejer; Marek Krawczyk; Wlodzimierz Ruka
Journal:  J Surg Oncol       Date:  2006-03-15       Impact factor: 3.454

9.  Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665.

Authors:  Burton L Eisenberg; Jonathan Harris; Charles D Blanke; George D Demetri; Michael C Heinrich; James C Watson; John P Hoffman; Scott Okuno; John M Kane; Margaret von Mehren
Journal:  J Surg Oncol       Date:  2009-01-01       Impact factor: 3.454
  9 in total
  3 in total

Review 1.  Get the GIST? An overview of gastrointestinal stromal tumours.

Authors:  G A Watson; D Kelly; M Melland-Smith; J Gleeson; G McEntee; C M Kelly; J A McCaffrey
Journal:  Ir J Med Sci       Date:  2016-02-01       Impact factor: 1.568

2.  (18)FDG-PET at 1-Month Intervals Is a Better Predictive Marker for GISTs That Are Difficult to Be Diagnosed Histopathologically: A Case Report.

Authors:  Kazunori Otsuka; Masahiro Takahashi; Hiroshi Nanjo; Hideaki Miyazawa; Masatake Iida; Yuki Abe; Mario Jin; Hirohide Onishi; Manabu Hashimoto; Yuzo Yamamoto; Hiroyuki Shibata
Journal:  Case Rep Oncol Med       Date:  2011-10-11

3.  Prolonged Therapy with Imatinib Mesylate before Surgery for Advanced Gastrointestinal Stromal Tumor Results of a Phase II Trial.

Authors:  C Doyon; L Sidéris; G Leblanc; Y E Leclerc; D Boudreau; P Dubé
Journal:  Int J Surg Oncol       Date:  2012-12-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.